Purity as the New Frontier: How IVIG Quality is Redefining Patient Care

TEANECK, NJ – April 16, 2026 – In an increasingly competitive market for life-sustaining plasma therapies, a new battleground is emerging, one fought at the molecular level. GC Biopharma USA is poised to highlight this shift, announcing it will present new research on the purity of its intravenous immunoglobulin (IVIG) product, ALYGLO®, at the upcoming 2026 National Home Infusion Association (NHIA) Annual Conference in Denver.

The presentation will detail a comparative analysis of protein aggregation in ALYGLO® and four other commercial IVIG products. The findings, according to the company, demonstrate a favorable profile for ALYGLO®, a result that could have significant implications for patient safety and product selection as the demand for IVIG therapy continues its steep ascent.

The Challenge of a Surging Market

The global demand for IVIG is no longer a niche concern. Once primarily used for a small number of primary immunodeficiencies, these therapies are now a cornerstone treatment for a broadening spectrum of immune-mediated conditions. This surge is fueled by improved disease recognition, an aging population, and the expansion of approved indications. Consequently, the global IVIG market has grown into a multi-billion dollar industry, with manufacturers racing to keep pace.

This rapid expansion, however, presents a significant manufacturing challenge: balancing immunoglobulin yield with product purity, stability, and, most importantly, patient safety. The intricate process of deriving immunoglobulin from thousands of human plasma donations is a delicate dance of purification and concentration. A critical aspect of this process is the management of protein aggregates—clumps of immunoglobulin molecules that can form during manufacturing and storage.

“As demand for immunoglobulin therapy continues to grow with improved disease recognition, analytical characterization of IVIG preparations helps advance scientific understanding of the molecular properties of these therapies,” said Alan Huber, PharmD, Director of Medical Affairs at GC Biopharma USA, in a statement preceding the conference.

The Science of Aggregation and Patient Safety

For patients and many healthcare providers, the term "protein aggregate" is an obscure bit of pharmaceutical jargon. Yet, its clinical relevance is profound. An ideal IVIG solution consists primarily of single or paired immunoglobulin molecules (monomers and dimers), which are the active components of the therapy. Aggregates, or polymers, are larger clusters of these molecules. While some level of aggregation is unavoidable, higher concentrations can be problematic.

The human immune system is designed to identify and attack large, complex structures. When an IVIG product with a high level of aggregates is infused, it can trigger an immune response, leading to a range of infusion-related reactions such as fever, chills, and nausea. More seriously, these aggregates can increase the product's immunogenicity, potentially leading the body to develop antibodies against the therapy itself, reducing its effectiveness over time. This is a crucial consideration for patients with chronic conditions who rely on IVIG for a lifetime.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider protein aggregation a critical quality attribute (CQA) that must be carefully monitored and controlled. The research being presented by GC Biopharma directly addresses this CQA, providing a head-to-head comparison of molecular size distribution.

A Focus on Molecular Purity

GC Biopharma's upcoming poster, titled “Assessment of the Aggregation Profile of Commercially Available Intravenous Immunoglobulin Products,” will show that ALYGLO®'s purification process yields a high percentage of monomers and dimers while minimizing larger polymers and protein fragments. This profile, the company suggests, may help inform product selection strategies for clinicians aiming to reduce risks associated with aggregates.

The company attributes this profile to its multi-step manufacturing process, which has been refined over its 50-year history in plasma products. The process for ALYGLO® includes cold ethanol fractionation, multiple chromatography steps—including a novel cation-exchange (CEX) process dubbed G-XI™ Technology—and dual viral inactivation and removal steps with nanofiltration. This rigorous purification is designed to not only ensure viral safety but also to precisely control the final composition of the product, stripping out impurities and minimizing the formation of aggregates.

Empowering Care in the Home Setting

The choice to present this data at the NHIA conference is strategic. The home infusion industry is one of the fastest-growing sectors in healthcare, offering patients a more convenient and often more comfortable alternative to hospital or clinic-based infusions. As more patients, particularly those with primary immunodeficiency, receive their regular IVIG treatments at home, the emphasis on product tolerability and safety becomes even more acute.

In a hospital, a patient experiencing an infusion reaction has immediate access to a full clinical team. At home, while under the care of a skilled nurse, the threshold for managing adverse events is different. A product with a lower propensity to cause infusion reactions can provide greater peace of mind for the patient, their family, and the home infusion provider.

“As more patients receive IVIG therapy in home settings, GC Biopharma values the opportunity to engage with home infusion providers on the latest research and advances that support safe administration and high-quality patient care,” noted Stacey Ness, PharmD, a Medical Science Liaison at GC Biopharma USA.

As the IVIG landscape evolves, the conversation is shifting from mere availability to nuanced questions of quality and differentiation. The data from GC Biopharma contributes to a growing body of evidence that empowers clinicians to look beyond the brand name and consider the specific molecular characteristics of a therapy. For the thousands of patients who depend on these treatments, this deeper focus on the science of purity promises a safer and more predictable path to wellness.